BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18507204)

  • 1. Characteristics of breast cancer patients with central nervous system metastases: a single-center experience.
    Harputluoglu H; Dizdar O; Aksoy S; Kilickap S; Dede DS; Ozisik Y; Guler N; Barista I; Gullu I; Hayran M; Selek U; Cengiz M; Zorlu F; Tekuzman G; Altundag K
    J Natl Med Assoc; 2008 May; 100(5):521-6. PubMed ID: 18507204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.
    Kim HJ; Im SA; Keam B; Kim YJ; Han SW; Kim TM; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Noh DY; Heo DS; Park IA; Bang YJ; Ha SW
    J Neurooncol; 2012 Jan; 106(2):303-13. PubMed ID: 21938531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
    Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
    Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.
    Altundag K; Bondy ML; Mirza NQ; Kau SW; Broglio K; Hortobagyi GN; Rivera E
    Cancer; 2007 Dec; 110(12):2640-7. PubMed ID: 17960791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.
    Gonzalez-Angulo AM; Cristofanilli M; Strom EA; Buzdar AU; Kau SW; Broglio KR; Smith TL; Hortobagyi GN
    Cancer; 2004 Oct; 101(8):1760-6. PubMed ID: 15386311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system metastases in breast cancer.
    Kiricuta IC; Kölbl O; Willner J; Bohndorf W
    J Cancer Res Clin Oncol; 1992; 118(7):542-6. PubMed ID: 1624546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer subtypes and outcomes of central nervous system metastases.
    Arslan UY; Oksuzoglu B; Aksoy S; Harputluoglu H; Turker I; Ozisik Y; Dizdar O; Altundag K; Alkis N; Zengin N
    Breast; 2011 Dec; 20(6):562-7. PubMed ID: 21871802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain metastases in breast cancer: prognostic factors and management.
    Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
    Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
    Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine therapy of central nervous system metastases from breast cancer.
    Ekenel M; Hormigo AM; Peak S; Deangelis LM; Abrey LE
    J Neurooncol; 2007 Nov; 85(2):223-7. PubMed ID: 17611719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
    Le Rhun E; Bertrand N; Dumont A; Tresch E; Le Deley MC; Mailliez A; Preusser M; Weller M; Revillion F; Bonneterre J
    Eur J Cancer; 2017 Dec; 87():189-198. PubMed ID: 29103666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER-Medicare analysis.
    Sadetsky N; Hernandez A; Wallick CJ; McKenna EF; Surinach A; Colburn DE
    Cancer Med; 2020 Sep; 9(17):6216-6224. PubMed ID: 32667719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
    Lai R; Dang CT; Malkin MG; Abrey LE
    Cancer; 2004 Aug; 101(4):810-6. PubMed ID: 15305414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The shifting landscape of metastatic breast cancer to the CNS.
    Quigley MR; Fukui O; Chew B; Bhatia S; Karlovits S
    Neurosurg Rev; 2013 Jul; 36(3):377-82. PubMed ID: 23262837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
    Leyland-Jones B
    J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
    Jurczyszyn A; Grzasko N; Gozzetti A; Czepiel J; Cerase A; Hungria V; Crusoe E; Silva Dias AL; Vij R; Fiala MA; Caers J; Rasche L; Nooka AK; Lonial S; Vesole DH; Philip S; Gangatharan S; Druzd-Sitek A; Walewski J; Corso A; Cocito F; Vekemans MC; Atilla E; Beksac M; Leleu X; Davila J; Badros A; Aneja E; Abildgaard N; Kastritis E; Fantl D; Schutz N; Pika T; Butrym A; Olszewska-Szopa M; Usnarska-Zubkiewicz L; Usmani SZ; Nahi H; Chim CS; Shustik C; Madry K; Lentzsch S; Swiderska A; Helbig G; Guzicka-Kazimierczak R; Lendvai N; Waage A; Andersen KT; Murakami H; Zweegman S; Castillo JJ
    Am J Hematol; 2016 Jun; 91(6):575-80. PubMed ID: 26955792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome.
    Ben-Zion Berliner M; Yerushalmi R; Lavie I; Benouaich-Amiel A; Tsoref D; Hendler D; Goldvaser H; Sarfaty M; Rotem O; Ulitsky O; Siegal T; Neiman V; Yust-Katz S
    Breast Cancer Res Treat; 2021 Jan; 185(2):423-432. PubMed ID: 33037977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
    Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
    Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.